

Identification of a central network hub of key prognostic genes based on correlation between transcriptomics and survival in patients with metastatic solid tumors

Vladimir Lazar*, Eric Raymond*, Shai Magidi^{ID}, Catherine Bresson, Fanny Wunder, Ioana Berindan-Neagoe, Annemilai Tijeras-Rabaland, Jacques Raynaud, Amir Onn, Michel Ducreux, Gerald Batist, Ulrik Lassen, Fin Cilius Nielsen, Richard L. Schilsky, Eitan Rubin and Razelle Kurzrock

Abstract

Background: Dysregulated pathways in cancer may be hub addicted. Identifying these dysregulated networks for targeting might lead to novel therapeutic options.

Objective: Considering the hypothesis that central hubs are associated with increased lethality, identifying key hub targets within central networks could lead to the development of novel drugs with improved efficacy in advanced metastatic solid tumors.

Design: Exploring transcriptomic data (22,000 gene products) from the WINTHER trial ($N=101$ patients with various metastatic cancers), in which both tumor and normal organ-matched tissue were available.

Methods: A retrospective in silico analysis of all genes in the transcriptome was conducted to identify genes different in expression between tumor and normal tissues (paired t -test) and to determine their association with survival outcomes using survival analysis (Cox proportional hazard regression algorithm). Based on the biological relevance of the identified genes, hub targets of interest within central networks were then pinpointed. Patients were grouped based on the expression level of these genes (K -mean clustering), and the association of these groups with survival was examined (Cox proportional hazard regression algorithm, Forest plot, and Kaplan–Meier plot).

Results: We identified four key central hub genes—*PLOD3*, *ARHGAP11A*, *RNF216*, and *CDCA8*, for which high expression in tumor tissue compared to analogous normal tissue had the most significant correlation with worse outcomes. The correlation was independent of tumor or treatment type. The combination of the four genes showed the highest significance and correlation with the poorer outcome: overall survival (hazard ratio (95% confidence interval (CI))=10.5 (3.43–31.9) $p=9.12E-07$ log-rank test in a Cox proportional hazard regression model). Findings were validated in independent cohorts.

Conclusion: The expression of *PLOD3*, *ARHGAP11A*, *RNF216*, and *CDCA8* constitute, when combined, a prognostic tool, agnostic of tumor type and previous treatments. These genes represent potential targets for intercepting central hub networks in various cancers, offering avenues for novel therapeutic interventions.

Keywords: cancer, genes, prognostic markers, RNA, transcriptomic

Received: 9 April 2024; revised manuscript accepted: 18 September 2024.

Ther Adv Med Oncol

2024, Vol. 16: 1–14

DOI: 10.1177/
17588359241289200

© The Author(s), 2024.
Article reuse guidelines:
[sagepub.com/journals-
permissions](https://sagepub.com/journals-permissions)

Correspondence to:

Shai Magidi
Worldwide Innovative
Network Association—WIN
Consortium, 24, rue Albert
Thuret, Chevilly-Larue
94850, France
[shai.magidi@
winconsortium.org](mailto:shai.magidi@winconsortium.org)

Vladimir Lazar
Catherine Bresson
Fanny Wunder
Jacques Raynaud
Richard L. Schilsky
Worldwide Innovative
Network Association—WIN
Consortium, Villejuif,
France

Eric Raymond
**Annemilai Tijeras-
Rabaland**
Groupe Hospitalier
Saint Joseph, Oncology
Department Paris, France

Ioana Berindan-Neagoe
The Oncology Institute
“Prof. Dr. Ion Chiricuta,”
Iuliu Hatieganu University
of Medicine and Pharmacy,
Cluj-Napoca, Romania

Amir Onn
Sheba Medical Center,
Institute of Pulmonology,
Tel HaShomer,
Ramat-Gan, Israel

Michel Ducreux
Gustave Roussy,
Department of Medical
Oncology, Villejuif, France

University Paris-Saclay,
Department of Medical
Oncology, Orsay, France

Gerald Batist
Segal Cancer Centre,
Department of Oncology,
Jewish General Hospital,
McGill University,
Montréal, QC, Canada

Ulrik Lassen
Fin Cilius Nielsen
Rigshospitalet,
Copenhagen, Denmark

Eitan Rubin
Ben-Gurion University of
the Negev, The Shraga
Segal Department of
Microbiology, Immunology
& Genetics, Faculty of
Health Sciences, Be'er-
Sheva, Israel

Razelle Kurzrock
Medical College of
Wisconsin, Milwaukee,
Wisconsin, USA

*These authors
contributed equally

Introduction

The clinical benefit of approved drugs generally is reflected by an increase in median progression-free survival (PFS) and overall survival (OS), with durations ranging from several weeks to several months. Unfortunately, cancer cells develop resistance mechanisms, in particular when they are administered as monotherapies.¹⁻⁴ Indeed, networks dysregulated in malignancies evolve to resist common perturbations, such as the action of specific therapies, but are highly fragile when encountering rare ones. Identifying these rare disruptions can collapse entire oncogenic networks. Robust networks often become overly reliant on specific key components (genes), known as “hubs”. Dysregulated networks may be hub-addicted, meaning they develop a strong dependence on certain hubs, such as those involved in energy and metabolism, PI3K (phosphoinositide 3-kinase), Akt (serine/threonine kinase), or mTOR (mechanistic target of rapamycin kinase). Targeting these less common points with specific drugs could potentially collapse the entire network.¹⁻³ The association between hub genes and cancer lethality is supported by multiple studies, highlighting the importance of these genes in cancer progression and patient prognosis.⁵⁻⁷ Since hub centrality may breed lethality, the identification of key hub targets of central networks may represent an important driver of novel drug development programs, aiming to increase the overall efficacy of treatments in advanced metastatic solid tumors and consequently improve survival outcomes.

A variety of factors influence a patient’s clinical outcome, including intrinsic characteristics of the cancer and the effects of therapies. Intrinsic characteristics may include specific genes that are prognostic biomarkers or predictive biomarkers that should be differentiated. Prognostic markers are used to identify persons who are more likely than similar individuals without the biomarker to experience a certain outcome regardless of treatment.^{8,9} Predictive biomarkers enable the prediction of treatment response.^{8,9} Common examples of predictive biomarkers are genes such as estrogen receptor, HER2/neu in breast cancer, and EGFR mutations in non-small-cell lung cancer (NSCLC).^{9,10} Since prognostic biomarkers may reflect biologic processes, they can also be targets for modulation by pharmacologic intervention. For instance, HER2 positivity is a marker of poor prognosis in breast cancer but is also predictive of response to HER2 antibodies and small molecular HER2 inhibitors.^{11,12}

Here we present a panel of novel prognostic central hub biomarkers that are independent of tumor type. Mandating prospective analyses, these genes could also potentially be predictive and be targeted with a novel generation of specific interceptors (drugs) developed to collapse central hub key genes within dysregulated networks and thus enhance the performance of targeted therapies for patients with metastatic solid tumors and prolong survival.

Materials and methods

The reporting of this study conforms to the STROBE statement.¹³

Dataset

The analysis presented in this study used the dataset generated by the WINTHER clinical trial which included a cohort of 101 patients with various metastatic cancer in multiple clinical sites across the world (France, Spain, Israel, and Canada).¹⁴ In all, 34 patients had colorectal carcinomas (CRC), 20 patients had head and neck (HN) carcinomas, 18 patients had NSCLC, and the remaining 29 patients had a variety of other types of cancers (breast, bladder, liver, melanoma, gastrointestinal, etc.). The patients’ median age was 59 years, 60% were males, and 40% were females. Patients had one to seven previous lines of treatment before enrollment in the WINTHER trial, with a median of three previous lines. The WINTHER trial did not include randomization or blinding approaches. The patients had available tumor and normal matched biopsies, a full profile of transcriptomic and genomics that informed the therapeutic choice, and clinical data including outcome—both PFS and OS. The OS in the WINTHER clinical trial was defined by the length of time from the start date of treatment to death or time last known to be alive, while the PFS was defined by the length of time from the start date of treatment to progression.¹⁴

In the WINTHER trial, it was demonstrated that the level of basal gene expression was highly variable between individuals and therefore a potential confounder of interpretation of gene expression in tumor tissue.¹⁴ Hence, to eliminate this variability, the transcriptomic expression level was assessed by comparing the tumor tissue to its normal histologic counterpart.

Statistical analysis

All the genes in the transcriptome (approximately 22,000 genes) were reviewed for association between their expression in the tumor tissue with the survival outcome (OS) using a survival analysis. The survival analysis was done using the Cox proportional hazard regression model using the “survival” and “survminer” packages in R.^{15–17} Patients who had missing expression values for the genes of interest in the survival analysis were excluded from the analysis. For that reason, some of the analyses include less than 101 patients. The level of significance (*p*-value) was corrected for multiple comparisons using the Benjamini and Hochberg method.¹⁸ Similarly, all genes in the transcriptome were reviewed for association between their expression in the normal tissue with the OS outcome. In the next step, we explored the difference between the expression of all genes in the tumor versus the normal tissues using a paired *t*-test with a 95% confidence interval (CI). Again, the *p*-values were adjusted using the false discovery rate methodology.¹⁸ At this point, we were able to search for genes that demonstrated high differences between the tumor and the normal tissues, and also to identify which of these genes (in tumor and normal tissues separately), correlated with outcome (OS). The search was refined by focusing on genes that had less impact in the normal tissue, meaning the intensity in the tumor was higher than the intensity in normal. Testing the difference between the tumor and the normal gene expression was visualized using boxplots. The boxplots show the median (reflected by the line that divides the box into two parts) and the interquartile range (shown by the box itself). The points shown outside the box are outlier expression values. The significant difference between the expression values in the tumor and the normal was derived using a paired student *t*-test with 95% CI. By searching for the genes that had a high association with survival (OS) and a high impact on the tumor tissues, and by taking into consideration the biological relevance, we were able to identify four genes (Figure 1).

We investigated the survival analysis of each of the four selected genes alone and in combination. The patients from the WINTHER trial were classified based on the level of expression of the four genes into “high” and “low” groups using the *K*-means clustering ($K=2$) method. *K*-means is an unsupervised machine learning algorithm used for the portioning of a dataset into *K* distinct non-overlapping clusters, minimizing the

within-cluster sum of squares.¹⁹ The “high” and “low” groups were then used in the Cox proportional hazard regression model to test the association of these groups with survival (OS). When considering the genes in combination, the patients were classified as “low” if all four genes were classified as “low”. Similarly, the patients were classified as “high” if all four genes were classified as “high”. Patients with a mixture combination of “low” and “high” were classified together in a third group called “others”. The analysis included investigations using the Forest plot and Kaplan–Meier (KM) plot. In the Forest plot, we investigated the association between multiple variables used to subgroup patients from the study with the survival outcomes. Patients were grouped by the variables of sex, site/type of the tumor, and the combined expression of the four genes. Each line in the Forest plot displays the hazard ratio (HR) and CI for an individual subgroup. For each variable, we used the HRs (shown as a square) to indicate the effect of the variable on the risk for an event (progression or death) to occur. HRs greater than 1 indicate increased risk, while HRs less than 1 suggest reduced risk. The CI (indicated as the length of the horizontal lines) indicates the precision of the estimates. Shorter lines indicate more precise estimates, while longer lines suggest less precision.

In the KM analysis, we estimated the survival probabilities over time and compared the survival rates of the patients from the gene expression groups. The log-rank test was used to determine the level of significance of the differences between the survival curves of the groups.

Validation

Validation of the four biomarkers for their survival prognostic potential was completed on independent publicly available datasets using the KM Plotter tool.²⁰ We used Chip-Seq mRNA datasets from breast cancer patients and RNA-Seq mRNA datasets including lung adenocarcinoma and kidney renal clear cell carcinoma patients. The four biomarkers were analyzed in a multivariable analysis taking the mean expression of the genes while assigning them an equal weight. The survival values that were used were OS. The datasets were taken as a whole, without filtering for histology type, stage, grade, gender, treatment groups, or any other characteristics. Biased arrays were excluded from the analysis. The cutoff for classifying the patients in each dataset into high and low expressers of the biomarkers was used by setting




Figure 1. Study design for finding hub genes and test their prognosis value.

an auto-select best cutoff, which resembles most of the *K*-mean clustering we implemented in our analysis on the WINTHER dataset.

Results

In continuity with the recently published digital display precision predictor (DDPP) algorithm correlating gene expression with clinical outcomes,²¹ we identified the genes whose tumor overexpression (compared to analogous normal) (*t*-test) significantly correlated with OS in the database of 101 patients with advanced solid tumors from the WINTHER trial, for whom gene expression (whole transcriptome—approximately 22,000 genes) in tumor and analogous normal tissues was available.

The criteria to select the most relevant genes were as follows: (1) higher association between OS and intensity of expression in the tumor based on the Cox proportional hazard regression model; (2) lower or no association between OS and intensity of expression in the normal tissue based on Cox proportional hazard regression model; (3) significant difference in expression between tumor and normal tissues (paired student's *t*-test); (4) greater impact on median OS; and (5) biological relevance. Based on these criteria (Figure 1), four genes were selected: *PLOD3*, *ARHGAP11A*, *RNF216*, and *CDCA8*, as described in Table 1.

Supplemental Figure 1(a)–(d) presents the paired student's *t*-test (boxplots) comparing the level of expressions in tumor and normal tissues, separately for each gene: *PLOD3* (adjusted

p-value = 5.76E–22), *ARHGAP11A* (adjusted *p*-value = 1.92E–06), *RNF216* (adjusted *p*-value = 8.06E–19), and *CDCA8* (adjusted *p*-value = 3.76E–10). Supplemental Figure 1(e)–(h) shows the KM survival analysis which was used to visualize the impact of the expression level of the genes selected (high and low) on OS separately for each gene—*PLOD3* (KM log-rank test *p* = 1.95E–06), *ARHGAP11A* (KM log-rank test *p* = 6.1E–06), *RNF216* (KM log-rank test *p* = 1.23E–05), and *CDCA8* (KM log-rank test *p* = 7.1E–05). The combined expression profile of the four genes, established by the level of its expression (high vs low), showed the highest significance and correlation with the outcome: OS *p* = 9.12E–07 and PFS *p* = 0.009 log-rank test, as shown in Figure 2(a) and (b), respectively. The cutoff low-high of the expression was determined by *K*-means clustering (*K* = 2), as described in the “Methods” section.

The association between conventional clinical and biological characteristics of the patients with OS is illustrated by the Forest Plot for the Cox proportional hazard regression model analysis (Figure 2(c)). This analysis investigated biological sex (male and female), site/type of the tumor: NSCLC, CRC, HN, and others; as well as ECOG status (0 and 1 vs >1), and the combined expression profile of the four genes (each classified into high vs low, as determined for each gene by *K*-means clustering): the “low” group includes patients in which all four genes classified as low, the “high” group includes patients in which all four genes classified as high, and the “other” group includes

Table 1. Main characteristics of the prognostic genes.

Gene symbol	KM OS adjusted p value (tumor)	KM OS adjusted p value (normal)	t.test adjusted p value (tumor vs normal)	Biological role ²²
<i>PLOD3</i>	0.014	0.479	3.49E-20	The membrane-bound homodimeric enzyme encoded by the <i>PLOD3</i> gene resides on the cisternae of the rough endoplasmic reticulum. The enzyme catalyzes lysyl residue hydroxylation in collagen-like peptides. The hydroxyllysyl groups that are created act as binding sites for collagen's carbohydrates and hence play a crucial role in intermolecular crosslink stability.
<i>ARHGAP11A</i>	0.03	0.832	9.13E-06	This gene codes for a Rho GTPase family of activator protein members. After DNA damage, this protein interacts with the tumor suppressor protein p53 and stimulates its tetramerization, which results in cell cycle arrest and programmed cell death. This gene is highly expressed in colon cancer and a human basal-like breast cancer cell line. A chromosomal deletion containing this gene is one of the causes of Prader-Willi syndrome.
<i>RNF216</i>	0.03	0.735	3.89E-17	<i>RNF216</i> gene encodes a cytoplasmic protein, which colocalizes and interacts with a RIP that is a protein kinase serine/threonine. Its zinc finger domains are crucial for both the interaction with the RIP and the suppression of IL1- and TNF-induced NF- κ B signaling. This protein can also act as an E3 ubiquitin-protein ligase, which takes up ubiquitin from E2 ubiquitin-conjugating enzymes and transfers it to substrates.
<i>CDC48</i>	0.046	0.555	2.88E-09	<i>CDC48</i> is part of the CPC. CPC is a regulator of mitosis. The CPC complex has key activity at the centromere, ensuring accurate chromosome segregation and assembly.

CPC, chromosomal passenger complex; KM, Kaplan-Meier; OS, overall survival; RIP, receptor-interacting protein; TNF, tumor necrosis factor.




Figure 2. Univariate and multivariate Cox proportional regression hazard survival models on WINTHER dataset. (a) KM shows the OS probability based on the level of expression of the prognostic genes in the tumor tissue ($n=96$). Patients with high expression across all four prognostic genes ($n=38$, red line) showed a median OS of 3.7 months. The median of the patients with low expression across all the prognostic genes ($n=14$, blue line) could not be obtained since at the last time point the survival probability was greater than 50%. All other patients ($n=44$, black line) showed a median OS of 7.4 months. (b) KM shows the PFS probability based on the level of expression of the prognostic genes in the tumor tissue. Patients with high expression across all four prognostic genes showed a median PFS of 1.6 months. Patients with low expression across all the prognostic genes showed a median OS of 6.7 months. All other patients showed a median OS of 2.3 months. (c) Forest plot which includes several covariates—sex, ECOG performance status, site of cancer tissue, and level of expression of the prognostic genes in the tumor tissue—demonstrates the survival hazard ratio of each (given as a point estimate along with the 95% CI in brackets). Hazard ratios greater than 1 (shown to the right with respect to the reference for each covariate) indicate better outcomes. p -Values (log-rank) with 95% CIs are shown in the plot for all the covariates included in the model. CI, confidence interval; KM, Kaplan-Meier; OS, overall survival; PFS, progression-free survival.

patients with all other combinations of a mixture of high and low. The HR of each characteristic with OS is shown in Figure 2(c). Taking ECOG 0 + 1 as a reference compared with ECOG > 1, the HR for high ECOG status was: HR=3.5 with a 95% CI (1.78–7.1) ($p=3.28E-04$). Taking, as a reference, the combined low expression of the four genes, the HR of the combined high expression group in all four genes was 10.5 with a 95% CI (3.43–31.9) ($p=3.69E-05$). The site of the tumors was not significantly associated with OS, confirming the agnostic tumor type trend of the analysis. Taken together, high versus low expression of genes *PLOD3*, *ARHGAP11*,

RNF216, and *CDCA8* constitutes an independent prognostic marker, agnostic of tumor type.

Supplemental Figure 2 illustrates the distribution of the site/type of the tumors and of the ECOG performance status of the patients in the WINTHER dataset per risk groups (low risk corresponds to patients who are classified with “low” expression level in all four genes, high risk corresponds to patients who are classified with “high” expression level in all four genes, and intermediate risk corresponds to all other patients).

Supplemental Figure 3 illustrates the enrichment distribution of *TP53* (3/14 (21.4%) vs 29/38

(76.3%) in the low- vs high-risk groups; $p = 0.0003$ (Chi-square)) and *RAS* mutations in the tumors at high risk (shortest OS) (1/14 (7.1%) vs 16/38 (42.1%) in the low- vs high-risk groups; $p = 0.04$ (Chi-square)) (highest risk group have high *PLOD3*, *ARHGAP11A*, *RNF216*, and *CDCA8*). EGFR alterations had very low frequency in all risk levels (4/96 (4%)). The distribution of the mTOR–Akt–PI3K pathway enrichment was shown in 24.8% (24/96) of all patients, mainly in the intermediate risk group (13/44 (29.5%)).

Validation in independent datasets

While the use of tumor and organ-matched normal tissues to determine comparative transcriptomic expression was essential for the identification and ranking of the four genes, once selected, we could perform correlative studies using the only expression in tumor biopsies. Validation of the four biomarkers panel for its survival prognostic potential was completed on independent publicly available datasets. Datasets were identified using the “KM plotter” tool described in the “Methods” section <http://kmplot.com/analysis/index.php?p=background>.²⁰

Figure 3 shows the KM survival probability plots in the independent cohorts constituted of patients with NSCLC adenocarcinomas (Figure 3(a)), breast cancers (Figure 3(b)), and renal clear cell carcinomas (Figure 3(c)).

The cohort of NSCLC adenocarcinomas (Figure 3(a)) consisted of 504 patients with stage I being 54%, stage II 23%, stage III 17%, and stage IV 6%. The correlation with OS was highly significant: HR=2.2 (1.51–3.21) with 95% CI (log-rank p -value=2.6E–05). Median survival in patients with low expression of the four genes is 77.27 months and in patients with high expression in the four genes is 40.97 months. The association between the identified genes and OS was also highly significant in the breast cancer cohort ($n = 943$, HR=1.64 (1.25–2.16) with 95% CI (log-rank p -value=3.8E–04)). Median survival in patients with low expression of the four genes is 136.8 months and in patients with high expression in the four genes is 63.83 months. For renal clear cell carcinoma: ($n = 530$, HR=1.61 (1.19–2.18) with 95% CI (log-rank p -value=0.0017)). Median survival in patients with low expression of the four genes is 48.77 months and in patients with high expression in the four genes is 28.87 months.

It is worthwhile to outline that these validation cohorts are different from WINTHER cohort,¹⁴ as they are tumor specific and include patients with all stages, and a high proportion of stage I, which are usually treated by surgery. Nevertheless, the prognostic signature is significantly associated with OS.

Therefore, we selected another independent validation dataset that focuses on metastatic disease. Figure 3(d) and (e) presents data from a neoadjuvant study in breast cancer in which only PFS was reported.²³ Figure 3(d) shows the KM PFS probability plot, with a significant correlation between the high expression of *PLOD3*, *ARHGAP11A*, and *CDCA8* (the expression of *RNF216* was not available in this dataset), and a shorter PFS ($p = 3.5E-05$). Figure 3(e) presents the Forest plot of the multivariate Cox regression hazard model showing the independent covariates that correlate with the outcome. The high expression of the three genes is an independent variable significantly associated with shorter PFS: HR: 8.46 (1.13–63.38) with a 95% CI ($p = 0.038$).

Discussion

The primary goal of any intervention in oncology is to improve OS and/or quality of life. A better understanding of cancer biology has led to the development of targeted therapies specifically designed to modulate an altered molecular pathway in cancer cells or their microenvironment. Despite the identification of molecular targets across cancer types, most targeted therapies were developed per cancer type.²⁴ Drug development, which in the past only considered the primary origin of the tumor, more recently included molecular targets present in the disease. Lung cancer is a striking example. Whereas EGFR mutations are quite frequent (10%–20% of Caucasian patients and 50% of Asian patients), several other actionable genomic alterations are less frequent, including but not limited to KRAS G12C mutation (13%), ALK translocation (5%), HER2 mutation (3%), MET activation (3%), BRAF V600 mutation (2%), and ROS1 translocation (1%).^{25–29} Therefore, biomarker strategies are now part of the standard of care. Most approved biomarker strategies include predominantly DNA sequencing and immunohistochemistry. Expanding investigations beyond DNA and integration of transcriptomics is still infrequent.³⁰ With few exceptions (Oncotype, MammaPrint), there is no consensus on the use of molecular transcriptomic




Figure 3. Multivariate analysis of *PLOD3*, *ARHGAP11A*, *RNF216*, and *CDCA8* in validation datasets. KM plots (a–d) show the survival probability based on the expression of the prognostic genes in different independent datasets.^{20,23} The patients in the validation cohorts were classified as “high” or “low” based on the expression of the prognostic genes. The number of patients surviving at each point in time as indicated by the x-axis is presented in the table below each plot. (a) RNA-Seq lung adenocarcinoma dataset.²⁰ HR = 2.2 (1.51–3.21) with 95% CI (log-rank *p*-value = 2.6E–05). Median survival in patients with low expression of the four genes is 77.27 months and in patients with high expression in the four genes is 40.97 months. (b) Chip-Seq breast cancer dataset.²⁰ HR = 1.64 (1.25–2.16) with 95% CI (log-rank *p*-value = 3.8E–04). Upper quartile survival in patients with low expression of the four genes is 136.8 months and in patients with high expression in the four genes is 63.83 months. (c) RNA-Seq kidney renal clear cell carcinoma dataset.²⁰ HR = 1.61 (1.19–2.18) with 95% CI (log-rank *p*-value = 0.0017). Upper quartile survival in patients with low expression of the four genes is 48.77 months and in patients with high expression in the four genes is 28.87 months. (d) KM plot showing the PFS probability in an Agilent microarrays breast cancer dataset.²³ (e) Forest plot multivariate Cox proportional hazard survival model analyses of main clinical biological and transcriptomics variables in an Agilent microarrays breast cancer dataset.²³ CI, confidence interval; HR, hazard ratio; KM, Kaplan–Meier.

signatures in the clinic, and the reason is mostly related to difficulties in the analytic interpretation of data, due to high interpatient variability.

Many current studies require tumor biopsy for omics interrogation. From the initial description in the BATTLE trial,³¹ the use of lung tumor biopsies spread in a few years and became part of

standard care, especially for obtaining genomic sequencing of DNA. However, next-generation studies, such as those described herein, may examine transcriptomics and, this has proven more challenging because of patient and organ heterogeneity that introduces analytic noise^{32,33}; moreover, requirements for quality of biopsies are more stringent for transcriptomics (fresh frozen

biopsies, a threshold of minimum 40%–50% content of tumor cells, and absence of contamination by surrounding tissue of the metastatic lesions selected for biopsies). In the current study, to address the interpatient variability of basal gene expression, we compared expression in organ-matched normal tissues from the same patient to the expression of genes in the tumor and, in continuation to the recently published novel algorithm DDPP,²¹ which demonstrated the feasibility of dual biopsies (tumor and normal tissues) and the development of novel RNA investigation tools that these biopsies enabled.^{14,21}

Expanding biomarker exploration to transcriptomics enabled us to address the measurement of genetic distance between tumor and normal cells, and use this comparison to prioritize the use of various targeted therapies in the WINTHER clinical trial.¹⁴ Our current study focuses on the identification of novel prognostic biomarkers, across tumor types, and using as a criterion of selection the correlation observed with the outcome (PFS and/or OS). The study was possible using the WINTHER dataset.¹⁴ Using the WINTHER pan-cancer dataset has the potential to enable the identification of common molecular and clinical features that influence prognosis across multiple cancer types.^{34–37} By understanding common pathways underlying cancer progression and metastasis, universal biomarkers that can serve as targets for therapeutic intervention can be identified and benefit patients across multiple cancer types.^{38–41}

A breakthrough occurred in the history of oncology when, for the first time, the FDA approved an anticancer drug based on a molecular alteration in a tissue-agnostic way. The first tumor-agnostic approval was for pembrolizumab, an immunotherapy mainly acting on T cells in patients with high microsatellite instability or a mismatch repair (MMR) deficiency.⁴² More recently, larotrectinib⁴³ and entrectinib^{44,45} and also other drugs obtained marketing authorization for tumors with molecular alterations in a tissue-agnostic way.⁴⁵ Following this trend of investigating biology agnostic of tumor type,⁴⁶ we explored the whole transcriptome to identify novel prognostic biomarkers, through the correlation of their expression and outcome. These genes were selected and ranked after exploring the whole transcriptome. High transcriptomic expression of these genes in tumors, as compared with organ-matched normal tissues, was significantly associated, with each gene independently with shorter

OS. When combined, high expression of *PLOD3*, *ARHGAP11*, *RNF216*, and *CDCA8* was significantly associated with shorter PFS and OS and may constitute a novel prognostic molecular signature, to identify those patients with the risk of the worst outcome.

It is worthwhile to mention that the collection of the paired tissue samples (tumor and normal-matched tissues), which allowed us to indicate the four genes, is not typically part of standard-of-care procedures. However, once discovered, the expression of the hub genes in the tumor tissue alone can be used to identify patients who might benefit from interceptors of these genes as targets. The data were validated in three independent datasets in NSCLC, breast, and kidney-renal cell carcinomas, beyond the WINTHER pan-cancer dataset that was used for discovery. The fact that the data were validated on heterogeneous independent datasets, which included patients across all disease stages and not just those in the metastatic stage, strengthens the findings. Nevertheless, we also included an independent breast cancer dataset that specifically contained samples from patients in the metastatic stage, to further bolster the robustness of our findings.

The association between high expression of certain genes and poor survival outcomes in cancer is well documented.^{47–50} Multiple studies have found that genes occupying central “hub” positions within gene regulatory networks tend to be linked to decreased survival in cancer patients.^{51–53} This indicates the importance of hub genes in cancer progression and patient prognosis. Based on the evidence from the literature, the four genes found in our analysis appear to have essential roles in central hub networks. This central positioning of the genes seems to be a common feature across many different tumor types.

Mutations of the *PLOD3* gene generate connective tissue disorders and over-expression promotes lung metastasis via regulation of *STAT3*.^{54,55} Our findings that the high *PLOD3* expression correlates with shorter OS (Supplemental Figure 1(e)) support its role as a driver of aggressive tumor behavior and suggest it could be a target for therapeutic strategies aimed at inhibiting metastasis. A recent study supports our findings and highlights the potential of *PLOD3* as a promising therapeutic target, showing that over-expression of *PLOD3* in CRC patients with liver metastasis is significantly

associated with poor outcomes.⁵⁶ In this study, we expand the findings on a pan-cancer cohort. *ARHGAP11A* is involved in the regulation of the Rho family of GTPases, which are critical in cell morphology, migration, and invasion. Blockade of *ARHGAP11A* reverses malignant progression via inactivating Rac1B in hepatocellular carcinoma.⁵⁷ Also, the prognosis value of *ARHGAP11A* alone was shown in clear cell renal cell carcinoma where high expression of the gene was associated with shorter survival.⁵⁸ The significant association between high *ARHGAP11A* expression and shorter OS observed in our pan-cancer study (Supplemental Figure 1(f)) supports its role in tumor progression and metastasis, making it a promising target for therapeutic intervention. *RNF216* interacts with receptor-interacting protein and inhibits tumor necrosis factor (TNF)- and IL1-induced NF-kappa B activation.⁵⁹ *RNF216* contributes to the proliferation and migration of colorectal cancer via suppressing BECN1-dependent autophagy.⁶⁰ The association of high *RNF216* expression with shorter survival (Supplemental Figure 1(g)) in our results highlights its potential as a prognostic marker and a therapeutic target to inhibit cancer cell proliferation and prolong survival. High expression of *CDC48* was found independent predictor for a poor prognosis in liver cancer.⁶¹ Overexpression of *CDC48* promotes the malignant progression of cutaneous melanoma and leads to poor prognosis.⁶² Our results reinforce the significance of *CDC48* in cancer prognosis and suggest that targeting *CDC48* could be a viable approach to controlling tumor growth and improving patient outcomes. The identification of these genes as significantly associated with shorter OS suggests that they play crucial roles in tumor biology and could serve as biomarkers. In addition, while these genes have already shown prognosis values in previous studies in various cancer types, as previously listed, the findings of this study expand their potential in an agnostic way. Targeting these genes could potentially lead to the development of new therapeutic strategies aimed at improving patient survival. For instance, inhibitors of *PLOD3*, *ARHGAP11A*, *RNF216*, and *CDC48* could be developed and tested in clinical trials, alone or in combinations, to assess their efficacy in reducing tumor growth and metastasis.

In addition to being agnostic to the tumor site, as shown in the Forest plot results, the four genes are also agnostic to type and number of previous

treatments (median of three previous lines). Although the number of previous lines of treatments is not shown as a biological characteristic in the Forest plot, it was tested and found insignificant.

One limitation is that the dataset size is limited. Increasing the size of the cohort would strengthen the results and reduce any variability that could be linked to ethnic differences between the patients. The findings need to be validated prospectively, especially when it comes to targeting the combination of all four genes.

Conclusion

Taken together, our findings are in line with numerous other observations pointing to a role of *PLOD3*, *ARHGAP11A*, *RNF216*, and *CDC48* in the pathogenesis of different types of solid tumors, suggesting their effects may be agnostic of tumor type. Our data suggest a prognostic value of high expression of these genes, alone and in particular in combination. Moreover, these results confirm and extend accumulating data reflecting the critical importance of assessing transcriptomic data to fully understand tumor biology.^{30,63–65}

Declarations

Ethics approval and consent to participate

The WINTHER study was conducted in accordance with the Declaration of Helsinki, and it was approved by the local Institutional Review Board (IRB) and Ethics Committees for each participating institution: (i) Research Ethics Office, Jewish General Hospital, Canada; (ii) CPP Ile de France III, France; (iii) Sheba Medical Center IRB committee, Israel; and (iv) CEIm Vall d'Hebron, Spain. Consent to participate: All patients provided written consent for research use of the results of the analysis of their biological samples. The analysis reported in this study does not disclose any identifiable information.

Consent for publication

All patients provided written consent for the publication of the results from research use of the analysis of their biological samples. The analysis reported in this study does not disclose any identifiable information.

Author contributions

Vladimir Lazar (V.L.): Conceptualization; Funding acquisition; Methodology; Project administration; Writing – original draft.

Eric Raymond (E.Ra.): Investigation; Resources; Writing – review & editing.

Shai Magidi (S.M.): Formal analysis; Project administration; Software; Visualization; Writing – review & editing.

Catherine Bresson (C.B.): Funding acquisition; Investigation; Project administration; Visualization; Writing – review & editing.

Fanny Wunder (F.W.): Data curation; Investigation; Writing – review & editing.

Ioana Berindan-Neagoe (I.B.N.): Conceptualization; Writing – review & editing.

Annemiläi Tijeras-Rabaland (A.T.R.): Investigation; Methodology; Resources; Writing – review & editing.

Jacques Raynaud (J.R.): Conceptualization; Funding acquisition; Writing – review & editing.

Amir Onn (A.O.): Conceptualization; Investigation; Writing – review & editing.

Michel Ducreux (M.D.): Conceptualization; Investigation; Writing – review & editing.

Gerald Batist (G.B.): Conceptualization; Investigation; Writing – review & editing.

Ulrik Lassen (U.L.): Conceptualization; Writing – review & editing.

Fin Cilius Nielsen (F.C.N.): Conceptualization; Writing – review & editing.

Richard L. Schilsky (R.L.S.): Conceptualization; Supervision; Writing – review & editing.

Eitan Rubin (E.Ru.): Formal analysis; Supervision; Validation; Writing – review & editing.

Razelle Kurzrock (R.K.): Conceptualization; Investigation; Supervision; Writing – original draft; Writing – review & editing.

Acknowledgements

In memory of Gaspard Bresson, John Mendelsohn, and Thomas Tursz who inspired the creation of the WIN Consortium.

Funding

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The research leading to these results has received funding from the European Union Seventh Framework Program (FP7/2007-2013 under grant agreement

no. 306125). Funded in part by ARC Foundation for Cancer Research (France), Pfizer Oncology, Lilly France SAS, and Novartis Pharmaceuticals Corporation. Funded in part by The Fero/J.P. Morgan Private Bank Clinical Oncology Research Grant, National Cancer Institute grant P30 P30-CA023100 (R.K.) and Israeli Science Foundation grant 1188/16 (E.Ru.), Instituto Salud Carlos III—Programa Rio Hortega Contract grant CM15/00255 (I.B.N.), and Canadian Institutes for Health Research (grant MOP-142281, G.B.) and the Canadian Cancer Society (grant 703811, G.B.).

Competing interests

V.L., C.B., and F.W. are full-time employees of the Worldwide Innovative Network (WIN) Association—WIN Consortium. WIN Association—WIN Consortium is the owner of the patent family entitled Digital Display. The inventors are V.L. and S.M. E.Ra. receives consulting and is a shareholder of SCOR Health Science, GenoScience Pharma, and Stromacare, is a shareholder of Axoltis, is a Scientific Director of Institut des Vaisseaux et du Sang (IVS), is a member of the Board of Directors of Institut National du Cancer (INCa France). S.M. receives consultancy from WIN Association—WIN Consortium. A.O. receives consulting fees from Roche Israel, MSD Israel, Boehringer Ingelheim, and AstraZeneca. M.D. reports consulting or advisory role: Amgen, AstraZeneca, Bayer, Daiichi Sankyo, GlaxoSmithKline, Ipsen, Merck Serono, MSD, Pierre Fabre, Roche, Servier, Sotio, and Zymeworks. Speakers' bureau: Amgen, AstraZeneca, Bayer, Merck KgaA, MSD, Pierre Fabre, Pfizer, Roche, Servier, and Terumo. G.B. collaborates in formal clinical trial contracts, IITs, and in joint grants funded by Canadian and Quebec governments with Roche, Merck, Novartis, Astra-Zeneca, Bayer, Esperas, Aurka, Caprion, MRM. U.L. reports advisory board roles at Bayer, Pfizer, and Novartis. Research grants: BMS, Roche, Pfizer, Lilly, Incyte, and GSK. R.L.S. is the Chairman of the WIN Association—WIN Consortium. He declares Research Support: and continues to serve as the PI of the ASCO TAPUR trial. ASCO receives research grants from the following companies in support of this trial: AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, Genentech, Lilly, Merck, Pfizer, Seagen, TAIHO. He does not personally receive any compensation from these

companies; receives Consulting: he is a consultant to the following companies: Aadi Bioscience* Brylogyx, Cellworks*, Clarified Precision Medicine*, EQRx*, Illumina*, Scandion Oncology* ZephyrAI*, and receive compensation from those designated (*) in the last 2 years. Board Service: He is a member of the Board of Directors of the following companies and receives compensation from each: Clarified Precision Medicine and Leap Therapeutics. R.K. is Chief Medical Officer of the WIN Association—WIN Consortium. She has received research funding from Boehringer Ingelheim, Debiopharm, Foundation Medicine, Genentech, Grifols, Guardant, Incyte, Konica Minolta, MedImmune, Merck Serono, Omniseq, Pfizer, Sequenom, Takeda, and TopAlliance and the NCI; as well as consultant and/or speaker fees and/or advisory board/consultant for Actuate Therapeutics, AstraZeneca, Bicara Therapeutics, Inc., Biological Dynamics, Caris, Datar Cancer Genetics, Daiichi, Eisai, EOM Pharmaceuticals, Iylon, LabCorp, Merck, NeoGenomics, Neomed, Pfizer, Prosperdtx, Regeneron, Roche, TD2/Volastra, Turning Point Therapeutics, X-Biotech; has an equity interest in CureMatch Inc. and IDbyDNA; serves on the Board of CureMatch and CureMetrix, and is a co-founder of CureMatch. I.B.N., A.T.R., J.R., F.C.N., and E.Ru. report no competing interests. All authors have read the policy of conflicts of interests.

Availability of data and materials

The data generated in this study are available upon request from the corresponding author on reasonable request at: <https://drive.google.com/drive/folders/1O7LVwb48FNJltfg-Y6CgrBXWay8vrDIV?usp=sharing>

ORCID iD

Shai Magidi  <https://orcid.org/0000-0003-4012-0544>

Supplemental material

Supplemental material for this article is available online.

References

- Carlson JM and Doyle J. Highly optimized tolerance: robustness and design in complex systems. *Phys Rev Lett* 2000; 84: 2529–2532.
- Weinstein IB. Addiction to oncogenes—the Achilles heel of cancer. *Science* (1979) 2002; 297: 63–64.
- Barabási A-L and Oltvai ZN. Network biology: understanding the cell's functional organization. *Nat Rev Genet* 2004; 5: 101–113.
- FDA. List of cleared or approved companion diagnostic devices (in vitro and imaging tools). U.S. Food and Drug Administration, <https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools> (2024, accessed 4 April 2024).
- Wuchty S. Controllability in protein interaction networks. *Proc Natl Acad Sci U S A* 2014; 111: 7156–7160.
- Goh K-I, Cusick ME, Valle D, et al. The human disease network. *Proc Natl Acad Sci U S A* 2007; 104: 8685–8690.
- Taylor IW, Linding R, Warde-Farley D, et al. Dynamic modularity in protein interaction networks predicts breast cancer outcome. *Nat Biotechnol* 2009; 27: 199–204.
- FDA-NIH Biomarker Working Group. Understanding prognostic versus predictive biomarkers. In: *BEST (Biomarkers, Endpoints, and other Tools) resource* [Internet]. Silver Spring (MD): Food and Drug Administration (US), 2016.
- Oldenhuis CNAM, Oosting SF, Gietema JA, et al. Prognostic versus predictive value of biomarkers in oncology. *Eur J Cancer* 2008; 44: 946–953.
- Lukas A, Heinzl A and Mayer B. Biomarkers for capturing disease pathology as molecular process hyperstructure. *bioRxiv* 2019. DOI: 10.1101/573402.
- Ménard S, Fortis S, Castiglioni F, et al. HER2 as a prognostic factor in breast cancer. *Oncology* 2001; 61: 67–72.
- Yan M, Schwaederle M, Arguello D, et al. HER2 expression status in diverse cancers: review of results from 37,992 patients. *Cancer and Metastasis Rev* 2015; 34: 157–164.
- Von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *BMJ* 2007; 335(7624): 806–808.
- Rodon J, Soria JC, Berger R, et al. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. *Nat Med* 2019; 25: 751–758.

15. Therneau TM. Survival-package—a package for survival analysis in R, <https://CRAN.R-project.org/package=survival> (2023, accessed 17 July 2024).
16. Kassambara A, Kosinski M and Biecek P. Survminer: drawing survival curves using ‘ggplot2’, <https://CRAN.R-project.org/package=survminer> (2021, accessed 17 July 2024).
17. Berthold MR, Cebron N, Dill F, et al. KNIME: The Konstanz Information Miner. *Data Analysis, Machine Learning and Applications*, (2008; 319–326).
18. Benjamini Y and Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J R Statist Soc Ser B (Methodol)* 1995; 57: 289–300.
19. Zubair M, Iqbal MA, Shil A, et al. An improved K-means clustering algorithm towards an efficient data-driven modeling. *Ann Data Sci*. Epub ahead of print 2022. DOI: 10.1007/s40745-022-00428-2.
20. Gyorffy B, Surowiak P, Budczies J, et al. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. *PLoS One* 9(10): e111842.
21. Lazar V, Magidi S, Girard N, et al. Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival. *NPJ Precis Oncol* 2021; 5: 33.
22. GeneCards®. The human gene database, <https://www.genecards.org/#:~:text=GeneCards%C2%AE%3A%20The%20Human%20Gene,annotated%20and%20predicted%20human%20genes> (accessed 3 July 2024).
23. Hatzis C, Pusztai L, Valero V, et al. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. *JAMA* 2011; 305: 1873–1881.
24. du Rusquec P and Le Tourneau C. Drug development in tissue-agnostic indications. *Cancers* 2021; 13: 2758.
25. Sebastian M, Eberhardt WEE, Hoffknecht P, et al. KRAS G12C-mutated advanced non-small cell lung cancer: a real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). *Lung Cancer* 2021; 154: 51–61.
26. Pillai RN, Behera M, Berry LD, et al. HER2 mutations in lung adenocarcinomas: a report from the Lung Cancer Mutation Consortium. *Cancer* 2017; 123: 4099–4105.
27. Bustamante Alvarez JG and Otterson GA. Agents to treat *BRAF*-mutant lung cancer. *Drugs Context* 2019; 8: 212566.
28. Wolf J, Seto T, Han J-Y, et al. Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer. *N Engl J Med* 2020; 383: 944–957.
29. Janku F, Stewart DJ and Kurzrock R. Targeted therapy in non-small-cell lung cancer—is it becoming a reality? *Nat Rev Clin Oncol* 2010; 7: 401–414.
30. Lazar V, Zhang B, Magidi S, et al. A transcriptomics approach to expand therapeutic options and optimize clinical trials in oncology. *Ther Adv Med Oncol* 2023; 15: 17588359231156382.
31. Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: personalizing therapy for lung cancer. *Cancer Discov* 2011; 1: 44–53.
32. Koscielny S. Why most gene expression signatures of tumors have not been useful in the clinic. *Sci Transl Med* 2010; 2: 14ps2.
33. Ioannidis JPA. Why most published research findings are false. In: *Getting to good: Research integrity in the biomedical sciences*. Springer International Publishing, 2018, pp. 2–8.
34. Adashek JJ, Kato S, Sicklick JK, et al. If it’s a target, it’s a pan-cancer target: tissue is not the issue. *Cancer Treat Rev* 2024; 125: 102721.
35. Adashek JJ, Kato S, Sicklick JK, et al. Considering molecular alterations as pan-cancer tissue-agnostic targets. *Nat Cancer* 2023; 4: 1622–1626.
36. Chen F, Wendl MC, Wyczalkowski MA, et al. Moving pan-cancer studies from basic research toward the clinic. *Nat Cancer* 2021; 2: 879–890.
37. Kaubryte J and Lai AG. Pan-cancer prognostic genetic mutations and clinicopathological factors associated with survival outcomes: a systematic review. *NPJ Precis Oncol* 2022; 6: 27.
38. Zhu H, Hu X, Ye Y, et al. Pan-cancer analysis of PIMREG as a biomarker for the prognostic and immunological role. *Front Genet* 2021; 12: 687778.
39. Cui L, Chen J, Li C, et al. Systematic pan-cancer analysis reveals X-C motif chemokine receptor 1 as a prognostic and immunological biomarker. *Genes* 2023; 14(10). DOI: <https://doi.org/10.3390/genes14101961>.

40. Yang J, Wu X and You J. Unveiling the potential of HSPA4: a comprehensive pan-cancer analysis of HSPA4 in diagnosis, prognosis, and immunotherapy. *Aging* 2024; 16(3): 2517–2541.
41. Wang S, Zhang M, Sun H, et al. Multi-omics analysis of TLCD1 as a promising biomarker in pan-cancer. *Front Cell Dev Biol* 2023; 11: 1305906.
42. Marcus L, Lemery SJ, Keegan P, et al. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. *Clin Cancer Res* 2019; 25: 3753–3758.
43. Mullard A. FDA approves landmark tissue-agnostic cancer drug. *Nat Rev Drug Discov* 2018; 18: 7.
44. Marcus L, Donoghue M, Aungst S, et al. FDA approval summary: entrectinib for the treatment of NTRK gene fusion solid tumors. *Clin Cancer Res* 2021; 27: 928–933.
45. De Braud FG, Niger M, Damian S, et al. Alka-372-001: first-in-human, phase I study of entrectinib—an oral pan-trk, ROS1, and ALK inhibitor—in patients with advanced solid tumors with relevant molecular alterations. *J Clin Oncol* 2015; 33: 2517.
46. Adashek JJ, Subbiah V and Kurzrock R. From tissue-agnostic to N-of-one therapies: (r)evolution of the precision paradigm. *Trends Cancer* 2021; 7: 15–28.
47. Ucaryilmaz Metin C and Ozcan G. Comprehensive bioinformatic analysis reveals a cancer-associated fibroblast gene signature as a poor prognostic factor and potential therapeutic target in gastric cancer. *BMC Cancer* 2022; 22: 692.
48. Li X-Y, Ma W-N, Su L-X, et al. Association of angiogenesis gene expression with cancer prognosis and immunotherapy efficacy. *Front Cell Dev Biol* 2022; 10: 805507.
49. Shen G-Y, Huang R-Z, Yang S-B, et al. High SNHG expression may predict a poor lung cancer prognosis based on a meta-analysis. *BMC Cancer* 2023; 23: 1243.
50. Ramanathan R, Olex AL, Dozmorov M, et al. Angiopoietin pathway gene expression associated with poor breast cancer survival. *Breast Cancer Res Treat* 2017; 162: 191–198.
51. Ye Q and Guo NL. Hub genes in non-small cell lung cancer regulatory networks. *Biomolecules* 2022; 12: 1782.
52. Liu C, Chen Y, Deng Y, et al. Survival-based bioinformatics analysis to identify hub genes and key pathways in non-small cell lung cancer. *Transl Cancer Res* 2019; 8: 1188–1198.
53. Liu S, Zeng F, Fan G, et al. Identification of Hub genes and construction of a transcriptional regulatory network associated with tumor recurrence in colorectal cancer by weighted gene co-expression network analysis. *Front Genet* 2021; 12: 649752.
54. Salo AM, Cox H, Farndon P, et al. A connective tissue disorder caused by mutations of the lysyl hydroxylase 3 gene. *Am J Hum Genet* 2008; 83: 495–503.
55. Baik JH, Yun HS, Kwon GT, et al. PLOD3 promotes lung metastasis via regulation of STAT3. *Cell Death Dis* 2018; 9: 1138.
56. Ding M, Wang C, Hu J, et al. PLOD3 facilitated T cell activation in the colorectal tumor microenvironment and liver metastasis by the TNF- α /NF- κ B pathway. *J Transl Med* 2024; 22: 30.
57. Dai B, Zhang X, Shang R, et al. Blockade of ARHGAP11A reverses malignant progress via inactivating Rac1B in hepatocellular carcinoma. *Cell Commun Signal* 2018; 16: 99.
58. Yang H, Zhang H, Zhang L, et al. ARHGAP11A is a novel prognostic and predictive biomarker correlated with immunosuppressive microenvironment in clear cell renal cell carcinoma. *Int J Mol Sci* 2023; 24: 7755.
59. Chen D, Li X, Zhai Z, et al. A novel zinc finger protein interacts with receptor-interacting protein (RIP) and inhibits tumor necrosis factor (TNF)- and IL1-induced NF- κ B activation. *J Biol Chem* 2002; 277: 15985–15991.
60. Wang H, Wang Y, Qian L, et al. RNF216 contributes to proliferation and migration of colorectal cancer via suppressing BECN1-dependent autophagy. *Oncotarget* 2016; 7(32): 51174–51183.
61. Shuai Y, Fan E, Zhong Q, et al. CDCA8 as an independent predictor for a poor prognosis in liver cancer. *Cancer Cell Int* 2021; 21: 159.
62. Ci C, Tang B, Lyu D, et al. Overexpression of CDCA8 promotes the malignant progression of cutaneous melanoma and leads to poor prognosis. *Int J Mol Med* 2019; 43: 404–412.
63. Tsimberidou AM, Fountzilias E, Bleris L, et al. Transcriptomics and solid tumors: the next frontier in precision cancer medicine. *Semin Cancer Biol* 2022; 84: 50–59.
64. Lilljebjörn H, Orsmark-Pietras C, Mitelman F, et al. Transcriptomics paving the way for improved diagnostics and precision medicine of acute leukemia. *Semin Cancer Biol* 2022; 84: 40–49.
65. Martínez-Ruiz C, Black JRM, Puttick C, et al. Genomic–transcriptomic evolution in lung cancer and metastasis. *Nature* 2023; 616: 543–552.